AMPK inactivation has been associated with tumorigenesis in melanoma [44] and thyroid cancer [45], while its activation holds promise as a therapeutic target for preventing tumor development and progression in breast and hepatic cancers [46,47]. The gene discussed is PRKAA1; the disease is neoplasm.